471 related articles for article (PubMed ID: 24467481)
1. Optimizing nanomedicine pharmacokinetics using physiologically based pharmacokinetics modelling.
Moss DM; Siccardi M
Br J Pharmacol; 2014 Sep; 171(17):3963-79. PubMed ID: 24467481
[TBL] [Abstract][Full Text] [Related]
2. Prediction of pharmacokinetics prior to in vivo studies. II. Generic physiologically based pharmacokinetic models of drug disposition.
Poulin P; Theil FP
J Pharm Sci; 2002 May; 91(5):1358-70. PubMed ID: 11977112
[TBL] [Abstract][Full Text] [Related]
3. PBPK models for the prediction of in vivo performance of oral dosage forms.
Kostewicz ES; Aarons L; Bergstrand M; Bolger MB; Galetin A; Hatley O; Jamei M; Lloyd R; Pepin X; Rostami-Hodjegan A; Sjögren E; Tannergren C; Turner DB; Wagner C; Weitschies W; Dressman J
Eur J Pharm Sci; 2014 Jun; 57():300-21. PubMed ID: 24060672
[TBL] [Abstract][Full Text] [Related]
4. Physiologically Based Pharmacokinetic (PBPK) Modeling of Pharmaceutical Nanoparticles.
Li M; Zou P; Tyner K; Lee S
AAPS J; 2017 Jan; 19(1):26-42. PubMed ID: 27834047
[TBL] [Abstract][Full Text] [Related]
5. Physiologically based pharmacokinetic (PBPK) modelling tools: how to fit with our needs?
Bouzom F; Ball K; Perdaems N; Walther B
Biopharm Drug Dispos; 2012 Mar; 33(2):55-71. PubMed ID: 22228149
[TBL] [Abstract][Full Text] [Related]
6. Physiologically Based Pharmacokinetic modelling of drugs in pregnancy: A mini-review on availability and limitations.
Berezowska M; Sharma P; Pilla Reddy V; Coppola P
Fundam Clin Pharmacol; 2024 Jun; 38(3):402-409. PubMed ID: 37968879
[TBL] [Abstract][Full Text] [Related]
7. Recent advances in physiologically based pharmacokinetic and pharmacodynamic models for anticancer nanomedicines.
Byun JH; Han DG; Cho HJ; Yoon IS; Jung IH
Arch Pharm Res; 2020 Jan; 43(1):80-99. PubMed ID: 31975317
[TBL] [Abstract][Full Text] [Related]
8. Physiologically-based PK/PD modelling of therapeutic macromolecules.
Thygesen P; Macheras P; Van Peer A
Pharm Res; 2009 Dec; 26(12):2543-50. PubMed ID: 19847627
[TBL] [Abstract][Full Text] [Related]
9. Successful Prediction of Human Pharmacokinetics by Improving Calculation Processes of Physiologically Based Pharmacokinetic Approach.
Mayumi K; Ohnishi S; Hasegawa H
J Pharm Sci; 2019 Aug; 108(8):2718-2727. PubMed ID: 30876861
[TBL] [Abstract][Full Text] [Related]
10. The emerging role of physiologically based pharmacokinetic modelling in solid drug nanoparticle translation.
Siccardi M; Rannard S; Owen A
Adv Drug Deliv Rev; 2018 Jun; 131():116-121. PubMed ID: 29959958
[TBL] [Abstract][Full Text] [Related]
11. Integration of Engineered Delivery with the Pharmacokinetics of Medical Candidates via Physiology-Based Pharmacokinetics.
Yang Y; Zhang X
Methods Mol Biol; 2022; 2486():57-69. PubMed ID: 35437718
[TBL] [Abstract][Full Text] [Related]
12. Physiologically based pharmacokinetics joined with in vitro-in vivo extrapolation of ADME: a marriage under the arch of systems pharmacology.
Rostami-Hodjegan A
Clin Pharmacol Ther; 2012 Jul; 92(1):50-61. PubMed ID: 22644330
[TBL] [Abstract][Full Text] [Related]
13. Integration of dissolution into physiologically-based pharmacokinetic models III: PK-Sim®.
Willmann S; Thelen K; Lippert J
J Pharm Pharmacol; 2012 Jul; 64(7):997-1007. PubMed ID: 22686345
[TBL] [Abstract][Full Text] [Related]
14. PHRMA CPCDC initiative on predictive models of human pharmacokinetics, part 5: prediction of plasma concentration-time profiles in human by using the physiologically-based pharmacokinetic modeling approach.
Poulin P; Jones RD; Jones HM; Gibson CR; Rowland M; Chien JY; Ring BJ; Adkison KK; Ku MS; He H; Vuppugalla R; Marathe P; Fischer V; Dutta S; Sinha VK; Björnsson T; Lavé T; Yates JW
J Pharm Sci; 2011 Oct; 100(10):4127-57. PubMed ID: 21541937
[TBL] [Abstract][Full Text] [Related]
15. Coupled in silico platform: Computational fluid dynamics (CFD) and physiologically-based pharmacokinetic (PBPK) modelling.
Vulović A; Šušteršič T; Cvijić S; Ibrić S; Filipović N
Eur J Pharm Sci; 2018 Feb; 113():171-184. PubMed ID: 29054499
[TBL] [Abstract][Full Text] [Related]
16. Physiologically based pharmacokinetic modeling of nanoparticles.
Li M; Al-Jamal KT; Kostarelos K; Reineke J
ACS Nano; 2010 Nov; 4(11):6303-17. PubMed ID: 20945925
[TBL] [Abstract][Full Text] [Related]
17. Development and application of physiologically based pharmacokinetic-modeling tools to support drug discovery.
Lüpfert C; Reichel A
Chem Biodivers; 2005 Nov; 2(11):1462-86. PubMed ID: 17191947
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics, Metabolism, Distribution and Permeability of Nanomedicine.
Ravindran S; Suthar JK; Rokade R; Deshpande P; Singh P; Pratinidhi A; Khambadkhar R; Utekar S
Curr Drug Metab; 2018; 19(4):327-334. PubMed ID: 29512450
[TBL] [Abstract][Full Text] [Related]
19. Enabling personalized cancer medicine decisions: The challenging pharmacological approach of PBPK models for nanomedicine and pharmacogenomics (Review).
Vizirianakis IS; Mystridis GA; Avgoustakis K; Fatouros DG; Spanakis M
Oncol Rep; 2016 Apr; 35(4):1891-904. PubMed ID: 26781205
[TBL] [Abstract][Full Text] [Related]
20. Predictive Pediatric Modeling and Simulation Using Ontogeny Information.
Ince I; Solodenko J; Frechen S; Dallmann A; Niederalt C; Schlender J; Burghaus R; Lippert J; Willmann S
J Clin Pharmacol; 2019 Sep; 59 Suppl 1():S95-S103. PubMed ID: 31502689
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
